ClinicalTrials.gg
CompletedNCT00144963Updated Dec 12, 2019Results posted

Liposomal Vincristine Plus Dexamethasone in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

A Phase 1/2 interventional study of Vincristine Sulfate Liposomes Injection and Dexamethasone in Acute Lymphoblastic Leukemia, sponsored by Acrotech Biopharma Inc.. Completed at 3 sites in United States. Per ClinicalTrials.gov, last updated 2019-12-12.

Sponsored by Acrotech Biopharma Inc. (part of Aurobindo Pharma) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 63 studies testing dexamethasone in Precursor Cell Lymphoblastic Leukemia-Lymphoma — 11 open to participants now, 19 under way, 6 of them phase 3. Dexamethasone · Precursor Cell Lymphoblastic Leukemia-Lymphoma.

Enrollment
41st of 62
36 · median 49
Started
2002
with 3 others
Phase 1/2
8 of 63
3 open now
Registered
14th of 63
by date

Among the 63 studies testing dexamethasone in Precursor Cell Lymphoblastic Leukemia-Lymphoma, this one is the 41st largest by enrollment of the 62 interventional ones that give a count, is one of 4 that started in 2002, is one of 8 in phase 1/2, and was the 14th registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 472 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

11 of the 63 studies testing dexamethasone in Precursor Cell Lymphoblastic Leukemia-Lymphoma are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About dexamethasone

Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 370 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 95 (26%) set no upper age limit and 258 (70%) stop at 75 or younger; 248 take children under 18; 29 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies testing dexamethasone in Precursor Cell Lymphoblastic Leukemia-Lymphoma, or all of them as a file.
02

Study summary

The purpose of this study is to find the highest safe dose and to assess the anti-tumor effect of liposomal vincristine with dexamethasone in patients with relapsed or refractory acute lymphoblastic leukemia (ALL).

Read the detailed description

OBJECTIVES:

  • Determine the maximum tolerated dose (MTD) of liposomal vincristine given with dexamethasone in patients with relapsed or refractory acute lymphoblastic leukemia (ALL).
  • Determine the efficacy of liposomal vincristine given with dexamethasone in these patients.
03

Conditions studied

  • Acute Lymphoblastic Leukemia
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Previously treated, ALL (including lymphoblastic lymphoma and Burkitt's subtypes) with .
  • Performance status ≤3 ().
  • All ages are eligible. Those aged 12 years or older may be counted towards the MTD in the Phase I portion of the trial. Pediatric patients are eligible, but must be treated at a dose level previously tested in an adult (one full course).
  • Adequate liver function ( ≤2 x upper limit normal), and renal function (creatinine ≤2 x upper limit normal).
  • Negative pregnancy test in females of .
  • Patients with prior history of stem cell transplant are eligible if they meet all other eligibility requirements.

Exclusion criteria

Exclusion Criteria:

  • Active serious infection not controlled by oral or intravenous antibiotics.
  • Treatment with any agents or chemotherapy agents in the last 21 days before study entry, unless full recovery from side effects has occurred or the patient has rapidly progressive disease judged to be life threatening by the Investigator.
  • Concurrent treatment with other anti-cancer agents other than dexamethasone.
  • Known CNS leukemia or lymphoma requiring intrathecal or craniospinal radiation therapy or with CNS neuropathy limiting evaluation of study drug. Patients with controlled CNS disease (no progression signs or symptoms at the time of study entry) may be eligible after approval by the Principal Investigator. Lumbar puncture not required in asymptomatic patients.
  • Prior history of Grade 3 or 4 sensory or motor neuropathy related to chemotherapeutic treatment, or persistent Grade 2 or greater active neuropathy.
  • History of active neurologic disorders unrelated to chemotherapy (including familial neurologic diseases and acquired demyelinating disorders).
  • Prior history of reactions to vincristine or any of the other components of VSLI.
  • Pregnant and/or lactating women; or fertile men or women not willing to use .
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    VSLI

    Vincristine Sulfate Liposomes Injection (VSLI)

    Drug: Vincristine Sulfate Liposomes Injection · Drug: Dexamethasone

Interventions

  • Study treatment consists of infusion of VSLI intravenously over 60 minutes on Day 1 and Days 8, 15 and 22 (+/- 2 days).

    Also known as: Marqibo

  • Study treatment consists of 40 mg dexamethasone, daily orally or intravenously, on Days 1-4 (+/- 2 days) and Days 11-14 (+/- 2 days).

06

What researchers measure

Primary outcomes

  1. MTD of VSLI

    Subjects had to receive at least 1 course consisting of 4 weekly infusions of VSLI at the assigned drug dose with a minimum 2 weeks of observation after the last VSLI dose to be included in the evaluation of the MTD.

    Time frame: 6 weeks

07

Results

Posted Jan 18, 2012

Participant flow

Participant flow — Overall Study
MilestoneVSLI
Started36
Completed36
Not completed0

Outcome measures

PrimaryMTD of VSLI

Subjects had to receive at least 1 course consisting of 4 weekly infusions of VSLI at the assigned drug dose with a minimum 2 weeks of observation after the last VSLI dose to be included in the evaluation of the MTD.

Time frame:
6 weeks
Reported as:
Number · mg/m2
MTD of VSLI
mg/m2VSLI
MTD of VSLI2.25

Adverse events

Collected over start of dosing until 30 days after permanent discontinuation of study treatment or until permanent discontinuation of study treatment and initiation of a subsequent anti-leukemia therapy. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
VSLI—33/36 (91.7%)36/36 (100%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventVSLI
BacteraemiaInfections and infestations17/36
febrile neutropeniaBlood and lymphatic system disorders12/36
pyrexiaGeneral disorders10/36
hypotensionVascular disorders7/36
abdominal painGastrointestinal disorders4/36
Pneumonia, fungalInfections and infestations3/36
neutropeniaBlood and lymphatic system disorders3/36
dehydrationMetabolism and nutrition disorders3/36
pneumoniaInfections and infestations2/36
oesophagitisGastrointestinal disorders2/36
Most frequent other events
Showing 10 of 110
Most frequent other events
EventVSLI
constipationGastrointestinal disorders24/36
fatigueGeneral disorders22/36
neuropathy peripheralNervous system disorders19/36
pyrexiaGeneral disorders18/36
anaemiaBlood and lymphatic system disorders17/36
nauseaGastrointestinal disorders17/36
abdominal painGastrointestinal disorders16/36
insomniaPsychiatric disorders16/36
hyperglycaemiaMetabolism and nutrition disorders15/36
diarrhoeaGastrointestinal disorders15/36

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)VSLI
<=18 years0
Between 18 and 65 years33
>=65 years3
Age, Continuous
Age, Continuous(years)VSLI
Mean36.3 ± 13.83
Sex: Female, Male
Sex: Female, Male(Participants)VSLI
Female12
Male24
Region of Enrollment
Region of Enrollment(participants)VSLI
United States36
08

Study locations

3 sites
  • Emory University
    Atlanta, Georgia 30322, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • University of Texas M.D. Anderson Cancer Center
    Houston, Texas 77030, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2002, a primary completion of Aug 2006 and a completion of Aug 2006. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2012, 5 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2005
First posted
Sep 5, 2005
Start
Jul 2002
Primary completionActual
Aug 2006
CompletionActual
Aug 2006
Results first posted
Jan 18, 2012
Last update
Dec 12, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00144963
Responsible party
Sponsor
First posted
Sep 5, 2005
Start date
Jul 2002
Primary completion
Aug 2006
Completion
Aug 2006
Results posted
Jan 18, 2012
Last update
Dec 12, 2019

Study contacts

Deborah Thomas, MD
principal investigator · MD Anderson Cancer Center, Department of Hematology/Oncology
Wendy Stock, MD
principal investigator · University of Chicago
Leonard Heffner, MD
principal investigator · Emory University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone

Start the discussion